anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method and apparatus implements patient data downloading for multiple different meter types, such as multiple different blood glucose meters. A plurality of serial ports is provided, each arranged for connection to a respective meter of the multiple different meter types. Information is displayed and user selections are identified. Responsive to user entry identifying a particular meter type, a connection port/cable number for the meter connection is displayed for viewing by the user. Predefined instructions for the particular meter type are displayed. A data collection computer system is provided as an integral unit including a unitary housing containing a processor device, a printer, and a display touch screen. When a meter connection is identified, information is displayed, patient data is downloaded from the meter and is printed in a selected format together with selected reports generated from the downloaded patient data.
PURPOSE:To provide a cosmetic composition effective to ameliorate the senile syndrome such as gray hair, spot (especially senile spot), and having high safety, by removing the head, tail and the fat surrounding the guts of Laticauda Semifasasciata (a kind of sea snake), and using the powder and/or extract of the bone, meat and skin as essential component. CONSTITUTION:The head, tail and the fat surrounding the guts of Laticauda Semifasasciata are removed, and the residual parts, i.e. the bones, meat and skin are pulverized and/or extracted. The powder and/or extract are used as the essential components of the objective cosmetic composition. The amount of the component in the composition is preferably about 10-5,000 ppm in terms of extract. the cosmetic composition prepared thereby has excellent dermatic cell activation effect resulting in the amelioration of the spot, senile spot, chapping, etc., especially exhibits high amelioration effect of gray hair when applied to the hair and has high safety.
Risk Summary

There are no data on the presence of pegvaliase-pqpz in human milk, the effects on the breastfed infant, or the effects on milk production. A pre-/post-natal study in rats showed that pegvaliase-pqpz is present in rat milk and that administration of pegvaliase-pqpz during lactation decreased pup weight and survival [see Use in Specific Populations (8.1)]. However, systemic absorption of pegvaliase-pqpz was not detected in the rat pups. Palynziq may cause low phenylalanine concentrations in human milk. The developmental and health benefits of breastfeeding should be considered along with the clinical need for Palynziq treatment and any potential adverse effect on the breastfed infant from Palynziq or from the underlying condition (see Clinical Considerations).

Clinical Considerations

Monitor blood phenylalanine concentrations in breastfeeding women treated with Palynziq.
Corona virus disease (COVID-19) is a disease caused by a new corona virus called Severe Acute Respiratory Syndrome Corona virus 2 (SARS-CoV-2). On March 11, the WHO Director-General declared COVID-19 a pandemic1. The first outbreak occurred in Wuhan, China. 2,3 COVID-19 pandemic has severely affected global health services.4 It is important not to overlook the value of some public health preventive interventions which cannot be postponed, such as vaccinations.5 As reported by WHO, the disruption of immunization services, even for brief periods, will result in increased numbers of susceptible individuals, raising the risks of an upsurge in outbreak-prone VPDs.6 The reduction of vaccination coverage could cause an increase in morbidity and mortality among children. Consequently, a greater burden could be placed on health systems. Examples from previous large epidemics (e.g. diphtheria in the former Soviet Union in 1990-1996 and in Venezuela in 2017-2018) show that, when vaccination coverage falls or vaccinations are disrupted, cases of infectious diseases that have disappeared can quickly re-emerge.7-8 Egypt declared a national state of emergency to control COVID-19 pandemic and implemented a stay-at-home order. Such strategies might result in decreased accessibility to routine immunization services, leaving children at risk for vaccine-preventable diseases and their complications.9 Great efforts are needed for rapid catch-up of children not up-to-date with routine vaccines. Parental concerns about potentially exposing their children to COVID-19 during vaccination visits might contribute to incompalince.10 Reminding parents of the vital need to protect their children against serious vaccine-preventable diseases is critical.
Single group assignment-Post lymphodepletion, JNJ-68284528 single infusion given to Part A participants: Cohort A(Progressive disease post 1-3 prior lines of therapy), Cohort B(Early relapse post front-line), Cohort C(Relapsed/refractory multiple myeloma post PI, IMiD,anti-CD38,anti-BCMA therapy), Cohort D(Less than CR post ASCT front-line therapy, some participants will receive JNJ-68284528 then lenalidomide), Cohort F(Newly diagnosed multiple myeloma \[NDMM\], standard risk \[International Staging System Stage I/II\] and post initial therapy); Cohort E(NDMM,transplant not planned,high risk disease) will first receive quadruplet induction regimen of daratumumab,bortezomib,lenalidomide and dexamethasone(D-VRd) then lymphodepletion and JNJ-68284528 then consolidation regimen of lenalidomide. Part B:Cohort G(NDMM,transplant not planned) will receive daratumumab, lenalidomide and dexamethasone followed by cilta-cel; Cohort H(NDMM,transplant-eligible) will receive D-VRd followed by cilta-cel.
Method for assessing and mitigating risk of adverse medical events including unplanned healthcare and / or death. The method involves obtaining existing accident and emergency, inpatient and outpatient healthcare data. The existing healthcare data, a pre-defined set of medical conditions and patient characteristics are used to build and deploy a machine learning model. First healthcare data generated at a time later than existing healthcare data is obtained. The predictive model processes first healthcare data to predict individual patients' risks of adverse medical event(s) 310. A target set of patients whose risk is greater than a threshold level is identified 312. Communication indicative of said target set of patients is sent to data source(s) and / or first device(s) associated with healthcare professional(s), healthcare intervention(s) mitigating adverse medical event(s) are determined 314. Optionally intervention(s) are determined by a healthcare professional or a system processor. Patient characteristics may include age, gender, ethnicity, social and economic deprivation. Vulnerability scores may be determined for each patient. The model may be trained and tested using k-fold cross validation.
A roentgen contrast medium comprises a suspension in a non-irratating, non-toxic fluid containing a suspending agent, of a mixture of a particulate roentgen-ray absorbing substance and a particulate, therapeutically acceptable, cellular material insoluble in water and in gastro-intestinal juices, which, since it contains closed air- or gas-filled cells, is of low density, the proportions of the components being such that the suspension has a density in the range 0.8 to 1.1 g/cm.3  The roentgen-ray absorbing substance may be barium sulphate or bismuth subcarbonate.  The lower density material may be particulate cellular plastic such as polystyrene, polyethylene, polyvinyl chloride, polytetrafluoroethylene or polyurethane; or a natural product with closed cells, e.g. cork meal, wood meal, infusorical earth and cellulose acetate.  Suitable suspending agents are vegetable mucilage, e.g. carrageen, agar and alginate.  The low-density particles may be admixed or coated with the roentgen-ray absorbing substance and suspended in the fluid, preferably water, containing the suspending agent. Alternatively, they may be incorporated in a suspension of the roentgen-ray in said fluid.
This is a single arm, single stage Phase II study designed to evaluate progression free survival (PFS) in patients with metastatic pancreatic cancer who have failed at least one prior line of therapy and treatment with gemcitabine. This study is open at the Levine Cancer Institute (LCI). A total of 32 patients will be enrolled over a two years. Following informed consent and eligibility check, all patients will start oral regorafenib therapy (120 mg daily for 3 weeks on / 1 week off; 28 day cycle) with a built-in dose escalation to 160mg after the first cycle as tolerated, and will continue therapy until progression or patient withdrawal. Patients will undergo radiological staging after the first two cycles of regorafenib therapy. Patients with progressive disease will be removed from the study. Patients who have at least stable disease will continue regorafenib therapy, at the Investigator's discretion, and will be radiologically restaged bimonthly.
The invention discloses a freshly-squeezed paulownia flower spray-dried powdery decoction piece and a preparation technology thereof. The preparation technology comprises the following steps: after the paulownia flowers are harvested, picking qualified paulownia flowers, washing selected paulownia flowers, squeezing the fresh paulownia flowers, filtering the juice, adding water into the residues, filtering, squeezing; merging the juice, carrying out reduced pressured concentration, spray-drying the liquid, collecting the spray-drying product, grinding the obtained solids, and packaging the powder into vacuum bags. The provided preparation method maximally preserves the polar and non-polar effective components in paulownia flowers. The decoction piece is convenient for transportation, storage, and blending, the quality is controllable, and the curative effect is reliable. The preparation technology has an important meaning for ensuring the clinical curative effect of traditional Chinese medicine. The provided decoction piece can generate prominent social benefits and economic benefits.
Embodiments of the invention are directed to methods of providing data feeds from medical devices associated with patients to computing devices associated with clinicians. A computing device for each of a number of clinicians is registered as being associated with the clinician. An identification of a patient is received. A list of medical devices related to the patient is retrieved. An identification of a number of clinicians is received. The medical devices are associated with the computing devices of the clinicians. Data feeds are provided to the computing devices from the medical devices.
Patients who are randomised to the CBT-TLIF group will have cortical bone trajectory screws instead of pedicle screws During the opreation. After preventive use of antibliotics,A small skin incision was made at the fused segment, an entry point for insertion of the CBT screws was drilled in the junction of the center of the superior articular process and 1 mm inferior to the inferior border of the transverse process according to Matsukawa et al.A straight probe was used to create a trajectory for the CBT screws from the entry point to the opposite corner of the pedicle and vertebral body under anteroposterior fluoroscopic guidance.nilateral facetectomy is performed to gain access to the intervertebral disc.Afterwards, interbody fusion was performed.Device: CBT screws.
The initial gemcitabine administration was on day 7 following IRE treatment. Once weekly infusions for 3 consecutive weeks out of every 4 weeks.Treatment continued until disease progression was detected by mRECIST or there was unacceptable toxicity.
BACKGROUND: Wrist arthroscopy is a standard procedure in hand surgery for the diagnosis and treatment of wrist conditions. While perioperative antibiotic prophylaxis (PAP) is not generally recommended for elective hand surgery, there is no official standard for elective wrist arthroscopy. This study aimed to determine the actual clinical use of PAP in elective wrist arthroscopy in Germany and relate it to the structural conditions of clinics performing this procedure.
MATERIAL AND METHODS: We conducted a systematic search of all facilities in Germany offering wrist arthroscopy. Among these, we performed an online survey using the SoSci Survey online tool via email.
RESULTS: PAP is more frequently administered in cases involving simultaneous bone procedures. Cephalosporins are the most commonly used antibiotics in cases of PAP administration. Hospitals administer PAP more frequently than outpatient settings, with most surveyed institutions following facility-specific internal standards for antibiotic administration. The number of arthroscopies performed in the surveyed centres does not influence antibiotic administration.
CONCLUSIONS: The use of PAP in wrist arthroscopies in Germany is inconsistent. The increased use in arthroscopies with bone involvement corresponds to AWMF guidelines, but a general recommendation for wrist arthroscopies, including soft tissue arthroscopies, is necessary to provide physicians with medical and legal certainty.
1348941 6,6-Difluorosteroids E I DU PONT DE NEMOURS & CO 22 April 1971 [22 April 1970 11 Jan 1971] 10823/71 Heading C2U The invention comprises compounds of formula wherein R is H or C 1-4  alkanoyl and R<SP>3</SP> is H or Me. The compounds with R = acetyl are prepared in a single step from compounds of formula (wherein X is Cl or F, and R<SP>2</SP> is H or C 1-4  alkanoyl) by reaction with silver acetate (optionally in the presence of sodium acetate, acetic acid and/or water) and then, if water was absent, contacting the product with water. The resulting 21-acetates may then be hydrolysed to 21-ols which may be re-alkanoylated. Compounds IV are prepared as described in Specification 1,348,943. Compounds I may be further converted as described in Specification 1,348,942. Pharmaceutical compositions for oral, parenteral and topical administration comprise a carrier and a compound of Formula I (the activity of which is not disclosed).
INTRODUCTION: Gastric emptying testing (GET) assesses gastric motility, however, is nonspecific and insensitive for neuromuscular disorders. Gastric Alimetry (GA) is a new medical device combining noninvasive gastric electrophysiological mapping and validated symptom profiling. This study assessed patient-specific phenotyping using GA compared with GET.
METHODS: Patients with chronic gastroduodenal symptoms underwent simultaneous GET and GA, comprising a 30-minute baseline, 99m TC-labelled egg meal, and 4-hour postprandial recording. Results were referenced to normative ranges. Symptoms were profiled in the validated GA App and phenotyped using rule-based criteria based on their relationships to the meal and gastric activity: (i) sensorimotor, (ii) continuous, and (iii) other.
RESULTS: Seventy-five patients were assessed, 77% female. Motility abnormality detection rates were as follows: GET 22.7% (14 delayed, 3 rapid), GA spectral analysis 33.3% (14 low rhythm stability/low amplitude, 5 high amplitude, and 6 abnormal frequency), and combined yield 42.7%. In patients with normal spectral analysis, GA symptom phenotypes included sensorimotor 17% (where symptoms strongly paired with gastric amplitude, median r = 0.61), continuous 30%, and other 53%. GA phenotypes showed superior correlations with Gastroparesis Cardinal Symptom Index, Patient Assessment of Upper Gastrointestinal Symptom Severity Index, and anxiety scales, whereas Rome IV Criteria did not correlate with psychometric scores ( P > 0.05). Delayed emptying was not predictive of specific GA phenotypes.
DISCUSSION: GA improves patient phenotyping in chronic gastroduodenal disorders in the presence and absence of motility abnormalities with increased correlation with symptoms and psychometrics compared with gastric emptying status and Rome IV criteria. These findings have implications for the diagnostic profiling and personalized management of gastroduodenal disorders.
UNLABELLED: The aim of this study is to train and test an ensemble of machine learning models, as well as to compare its performance with the BERT language model pre-trained on medical data to perform simple binary classification, i.e., determine the presence/absence of the signs of intracranial hemorrhage (ICH) in brain CT reports.
MATERIALS AND METHODS: Seven machine learning algorithms and three text vectorization techniques were selected as models to solve the binary classification problem. These models were trained on textual data represented by 3980 brain CT reports from 56 inpatient medical facilities in Moscow. The study utilized three text vectorization techniques: bag of words, TF-IDF, and word2vec. The resulting data were then processed by the following machine learning algorithms: decision tree, random forest, logistic regression, nearest neighbors, support vector machines, Catboost, and XGboost. Data analysis and pre-processing were performed using NLTK (Natural Language Toolkit, version 3.6.5), libraries for character-based and statistical processing of natural language, and Scikit-learn (version 0.24.2), a library for machine learning containing tools to tackle classification challenges. MedRuBertTiny2 was taken as a BERT transformer model pre-trained on medical data.
RESULTS: Based on the training and testing outcomes from seven machine learning algorithms, the authors selected three algorithms that yielded the highest metrics (i.e. sensitivity and specificity): CatBoost, logistic regression, and nearest neighbors. The highest metrics were achieved by the bag of words technique. These algorithms were assembled into an ensemble using the stacking technique. The sensitivity and specificity for the validation dataset separated from the original sample were 0.93 and 0.90, respectively. Next, the ensemble and the BERT model were trained on an independent dataset containing 9393 textual radiology reports also divided into training and test sets. Once the ensemble was tested on this dataset, the resulting sensitivity and specificity were 0.92 and 0.90, respectively. The BERT model tested on these data demonstrated a sensitivity of 0.97 and a specificity of 0.90.
CONCLUSION: When analyzing textual reports of brain CT scans with signs of intracranial hemorrhage, the trained ensemble demonstrated high accuracy metrics. Still, manual quality control of the results is required during its application. The pre-trained BERT transformer model, additionally trained on diagnostic textual reports, demonstrated higher accuracy metrics (p<0.05). The results show promise in terms of finding specific values for both binary classification task and in-depth analysis of unstructured medical information.
Rapid intravenous administration of Phenytoin Sodium Injection increases the risk of adverse cardiovascular reactions, including severe hypotension and cardiac arrhythmias. Cardiac arrhythmias have included bradycardia, heart block, ventricular tachycardia, and ventricular fibrillation which have resulted in asystole, cardiac arrest, and death. Severe complications are most commonly encountered in critically ill patients, elderly patients, and patients with hypotension and severe myocardial insufficiency. However, cardiac events have also been reported in adults and children without underlying cardiac disease or comorbidities and at recommended doses and infusion rates.

Intravenous administration should not exceed 50 mg per minute in adults. In pediatric patients, administer the drug at a rate not exceeding 1 to 3 mg/kg/min or 50 mg per minute, whichever is slower.

  


Although the risk of cardiovascular toxicity increases with infusion rates above the recommended infusion rate, these events have also been reported at or below the recommended infusion rate.

As non-emergency therapy, Phenytoin Sodium Injection should be administered more slowly as either a loading dose or by intermittent infusion. Because of the risks of cardiac and local toxicity associated with intravenous phenytoin, oral phenytoin should be used whenever possible.

Because adverse cardiovascular reactions have occurred during and after infusions, careful cardiac and respiratory monitoring is needed during and after the administration of intravenous Phenytoin Sodium Injection. Reduction in rate of administration or discontinuation of dosing may be needed.
OBJECTIVES: I. Assess the toxicity profile of irinotecan and amifostine when administered together in patients with metastatic colorectal cancer. II. Assess the total dose of irinotecan received per 6 week course in these patients. III. Determine the incidence of irinotecan-induced leukopenia, neutropenia, and diarrhea in these patients. V. Determine the response rate for this patient population.

OUTLINE: This is an open label study. Amifostine is administered by 10 minute IV infusions. Irinotecan is administered by IV infusions 15 minutes after completion of amifostine. Treatment is repeated every 2 weeks for 6 weeks. This 6 week course is repeated in the absence of disease progression. Treatment may be delayed up to 2 weeks after a course to allow for recovery from toxic effects. Patients are followed at the end of study and at 30 days after study.

PROJECTED ACCRUAL: There will be 25-30 patients accrued into this study.
1,217,029. Sulphuric and phosphoric acid esters of baicalein and salts. TAKEDA YAKUHIN KOGYO K.K. 14 Oct., 1968 [12 Oct., 1967; 9 Nov., 1967], No. 48530/68. Heading C2C. Novel sulphuric acid and phosphoric acid esters and partial esters of baicalein of formula and salts thereof with alkali and alkaline earth metals, ammonia amines and hydroxy amines are prepared by phosphorylating or sulphating of baicalein which may be in a crude form and optionally followed by salt formation. Pharmaceutical compositions in conventional forms for oral parenteral or rectal administration having anti-allergic action comprise an above novel compound or salt and a carrier therefor.
Aspects disclosed herein provide a method for optimizing a medical treatment plan. The method may include receiving kinematics data from a wearable sensor coupled to an instant patient, determining, based on the received kinematics data and stored information, a medical treatment plan. The procedure may include installation of an implant. Determining the medical treatment plan may include determining an alignment, position, design, or type of the implant. The stored information may include preoperative information for the instant patient and preoperative information, intraoperative information, and postoperative information from a plurality of previous patients having at least one characteristic in common with the instant patient. Each of the preoperative information, intraoperative information, and postoperative information may include kinematics data obtained using a previous wearable sensor.
Participants randomized to this arm will meet three times (Month 2; Month 5 and Month 10), in a group setting, during the intervention. Each group will have a maximum of 20-40 participants. This is a stand-alone activity, which is not associated with a donation event. During each meeting, participants will be asked to watch, in the group setting, an episode of drama, lasting 15 minutes. The docudrama on blood donation will address participant's concerns regarding blood donation and address common donor fears.
The study sample is drawn from persons referred to a falls outpatient clinic. Group exercise and home exercise are delivered by trained physiotherapists. Home exercise follows the original Otago exercise protocol. Group exercise is performed twice a week. The length of the intervention period is 3 months. The main outcome measure is the Berg Balance Scale.